New York, August 11, 2026, 09:50 EDT
- AbCellera stock surged 34% on Monday following the achievement of Phase 2 efficacy targets by ABCL635.
- By week four, a single dose lowered both the frequency and severity of hot flashes compared to placebo.
- None of the 92 participants in the trial discontinued treatment due to side effects.
Shares of AbCellera Biologics Inc. NASDAQ:ABCL jumped 34% on Monday following positive Phase 2 results for its investigational menopause treatment, which achieved both primary efficacy measures. The results position ABCL635 as the most significant asset in AbCellera’s internal pipeline.
The outcome is significant as a single subcutaneous injection was effective up to week four. ABCL635 lowered the frequency and intensity of moderate-to-severe hot flashes when compared to placebo. Participants additionally noted improvements in sleep and overall well-being.
The safety profile supported the findings. None of the 92 participants stopped due to side effects. This is significant for a therapy intended for otherwise healthy women coping with ongoing symptoms.
| Phase 2 measure | Trial detail | Reported result |
|---|---|---|
| Participants | 92 postmenopausal women | Randomized comparison finished |
| Dosing | Single subcutaneous dose | Activity monitored up to week four |
| VMS frequency | Change from baseline versus placebo | Main efficacy endpoint achieved |
| VMS severity | Change from baseline versus placebo | Main efficacy endpoint achieved |
| Tolerability | Discontinuations due to side effects | No cases reported |
The study used randomization and a placebo control. According to its registry, planned outcomes included frequency and intensity of symptoms and total hot-flash scores. The published summary noted statistical significance, but a detailed table of effect size was not provided.
ABCL635 is an inhibitor of the neurokinin 3 receptor (NK3R), which is involved in temperature control within the hypothalamus. AbCellera created this antibody to offer a nonhormonal, extended-duration therapy.
The monthly profile serves as the commercial fulcrum. Astellas Pharma Inc. (TYO:4503) and Bayer AG (ETR:BAYN) both market oral drugs targeting NK3R. A long-acting injection may offer reduced dosing frequency in exchange for daily dosing ease.
Stifel Financial Corp. NYSE:SF analyst Stephen Willey described the readout as “a best-case-scenario which clearly solidifies competitive differentiation.” He highlighted efficacy, safety and monthly dosing as reasons for his conclusion. Barron’s
The result supports previous pharmacology. In May, founder and CEO Carl Hansen stated ABCL635 had “achieved robust NK3R target engagement.” Phase 1 results indicated an estimated half-life of 24 days with no increase in liver enzymes. AbCellera Q1 release
| Q1 2026 measure | Value | Investor relevance |
|---|---|---|
| Cash and marketable securities | $531 million | Supports internal clinical programs |
| Available non-dilutive funding | About $124 million | Bolsters resources without issuing new equity |
| Total available liquidity | About $655 million | Liquidity position reported by company |
| Quarterly net loss | $43.2 million | Represents current burn rate |
| Quarterly R&D expense | $46.7 million | Indicates investment in R&D pipeline |
AbCellera posted these results for the quarter ending March 31. Its cash and marketable securities were 12.3 times greater than the net loss for the period. The figure is a simple ratio rather than official runway guidance, since spending and trial expenses may fluctuate.
Nevertheless, the ratio puts Monday’s repricing into perspective. Investors are shifting away from valuing ABCL635 solely on target engagement. They now have access to controlled data on efficacy and tolerability, and AbCellera still holds a strong funding position.
| Analyst | Rating | Price target | Published |
|---|---|---|---|
| Stifel Financial NYSE:SF | Buy | $8 | May 12, 2026 |
| Truist Financial Corp. NYSE:TFC | Buy | $12 | May 22, 2026 |
| Cantor Fitzgerald | Overweight | $11 | July 17, 2026 |
All three recommendations were released prior to the Phase 2 results. Stifel’s price target was based on Phase 1 outcomes, Truist’s estimate included potential menopause revenues, and Cantor reiterated its stance ahead of the data release. Upcoming updates from these analysts will reflect how the latest efficacy results impact their valuations.
The stock movement was significant, yet it came after a pivotal clinical development. AbCellera shares had risen over twofold in 2026 prior to Monday, Barron’s reported. Anticipation was high.
Risks: The research involved a limited group of participants and is in its initial phase. Confirmation of the advantages and detection of rarer adverse effects require larger-scale trials. Patients who favor daily tablets might not adhere to monthly injections, and investment in development could reduce the cash ratio.
The following step involves determining the development plan. A more extensive trial affirming the week-four results would justify the premium reflected in Monday’s 34% increase. If efficacy proves weaker or a new safety issue emerges, that reasoning would be overturned.
